Markets
← Back to Stocks
ABBV
ABBVIE INC
Health Care · Biotechnology
$206.31
-0.97%
Vol: 0.1M
Araverus Market Read
Thursday, March 19, 2026
J&J competing psoriasis approval and recent immunology investments balance overnight weakness in specialty pharma positioning
AbbVie declined $0.86 (-0.38%) in pre-market to $226.15 and rose $0.10 after-hours to $208.65, showing volatility around $227.01 close. Johnson & Johnson's FDA approval for competing psoriasis medication ICOTYDE caused 4.88% decline as investor concerns mounted about Rinvoq market competition. Positive developments including risankizumab dosing study advancement and Alloy Therapeutics partnership demonstrate continued immunology investment despite near-term competitive pressures.
Price 50d 200d
Previous Market Reads
2 of 2 days↑
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$364.6B
P/E (TTM)86.7
Forward P/E12.8
Beta0.33
Div Yield332.00%
Prev Close$208.33
RSI (14-Day)
17Oversold
0305070100
52-Week Range
$164.39$206.31$244.81
From High-15.7%
From Low+25.5%
Moving Averages
50d SMA
$223.44-7.7%
200d SMA
$212.93-3.1%
Price below 200d MA — bearish structure.
Returns
1W
-8.5%
1M
-9.8%
3M
-7.0%
6M
-5.1%
1Y
-0.3%
YTD
-9.3%
Volume
Today123K
20d Avg6.2M
Ratio0.02x